CJC-1295 DAC
- 99%+ HPLC Purity — Independently verified by accredited US laboratory
- Endotoxin-Screened — LAL tested, LPS-free, endotoxin report available
- GMP-Certified Manufacturing — USA facility, ISO 9001:2015
- Lyophilized for Stability — Shipped cold-packed, intact for reconstitution
Add essential supplies:
For laboratory research use only. Not for human or veterinary use.
About CJC-1295 DAC
CJC-1295 DAC is a synthetic growth hormone releasing hormone (GHRH) analogue carrying a Drug Affinity Complex modification. It is supplied here as a lyophilized powder at 99%+ HPLC purity for laboratory research use only.
This material is a research chemical. It is not a medicine, is not for human or veterinary use, and no dosing, administration or handling-in-humans guidance is provided.
What is CJC-1295 DAC?
CJC-1295 DAC is a synthetic analog of growth hormone releasing hormone. The DAC component is a modification that allows albumin binding, which published pharmacokinetic studies associate with an extended half-life relative to the unmodified sequence.
- Extended half-life: published pharmacokinetic literature reports a substantially longer half-life than CJC-1295 No DAC.
- GHRH receptor research: used as a reference compound in receptor-binding and signalling assays.
- Comparative studies: frequently paired with GHRP-class peptides such as Ipamorelin in laboratory protocol comparisons.
Published research context
The following summarises third-party laboratory and clinical pharmacology literature about the molecule. It is not a claim about this product, which is supplied for research use only.
Pharmacokinetics
Published studies have characterised plasma growth hormone and IGF-1 profiles following administration in controlled research settings.
Receptor pharmacology
In-vitro work has examined GHRH receptor binding and downstream signalling.
Analogue comparison
Literature compares DAC and No DAC variants with respect to duration of action in pharmacokinetic models.
Why researchers select this material
Laboratory handling characteristics reported for this compound:
- Well-characterised sequence and molecular weight for analytical verification.
- Extended-duration profile useful for comparative pharmacokinetic study design.
- Supplied at 99%+ HPLC purity with published batch documentation.
- Stable lyophilized format under recommended cold storage.
Frequently Asked Questions
CJC-1295 DAC: specification, blend option and pricing
CJC-1295 DAC is a synthetic growth-hormone-releasing-hormone analogue carrying a Drug Affinity Complex modification, CAS 863288-34-0, molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ at 3367.9 g/mol. It is supplied as a 2mg lyophilized vial at 99%+ purity, with further mg options and multi-vial tier pricing selectable above.
Researchers looking for the paired GHRH/GHRP combination can also order the pre-formulated CJC-1295 + Ipamorelin blend vial, or the standalone Ipamorelin and CJC-1295 No DAC vials, all listed in the catalog with their own batch documentation.
Published work on CJC-1295 DAC concerns GHRH receptor pharmacology and half-life extension in laboratory and animal models. Nothing here describes a human effect. Supplied for laboratory research use only — not for human or veterinary use.
- Strength: 2mg vial (additional mg options available)
- Purity: 99%+ HPLC · Reference LPCJC-01
- CAS 863288-34-0 · C₁₅₂H₂₅₂N₄₄O₄₂ · 3367.9 g/mol
- Form: lyophilized powder — research use only
Review the matching batch documentation in our HPLC testing library, compare strengths across the independently tested research peptide catalog, or ask about volume pricing on the bulk offers page.
